More Starpharma Holdings Limited news
Starpharma Holdings LimitedASX: SPL

VIRALEZE SPL7013 virucidal against multiple COVID variants

Jun 17, 2021 at 11:44 PM EDT · Issued by Starpharma Holdings Limited

Filed with ASX · Jun 17, 2021 at 11:44 PM EDT

On 6ix: 6ix.com/news/viraleze-spl7013-virucidal-against-multiple-covid-variants

Starpharma Holdings Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Starpharma Holdings Limited on 6ix

Story so far

  • VIRALEZE COVID-19 nasal spray study to commence in JanuaryDec 22, 2020
  • VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21Dec 10, 2020
  • SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2Sep 14, 2020

Earlier from Starpharma

  • VIRALEZE antiviral nasal spray registered for sale in IndiaJun 11, 2021
  • VIRALEZE SPL7013 highly active in UK variant of coronavirusJun 1, 2021
  • VIRALEZE launches in EuropeMay 6, 2021
  • VIRALEZE™ now launched by LloydsPharmacy in the UKMar 29, 2021
  • VIRALEZE to be launched with LloydsPharmacy in the UKMar 24, 2021

Later from Starpharma

  • VIRALEZE UK UpdateJun 20, 2021
  • VIRALEZE SPL7013 virucidal against SARS-CoV-2 Delta variantJul 27, 2021
  • VIRALEZE well tolerated in multiple dose clinical studyAug 17, 2021
  • VIRALEZE Protects Against SARS-CoV-2 in Challenge ModelAug 23, 2021
  • VIRALEZE launch in ADMENTA Italia Group pharmacies in ItalyOct 7, 2021
All Starpharma news releases↗

Follow Starpharma into a list and get an email when it puts out news.

Follow Starpharma
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer